iBB
58.0K views | +1 today
Follow
iBB
Institute for Bioengineering and Biosciences
Curated by iBB
Your new post is loading...
Your new post is loading...
Scoop.it!

Call for Submissions: Special Issue on "Novel Micro/Nanomaterials Based Drug Delivery Systems"

Call for Submissions: Special Issue on "Novel Micro/Nanomaterials Based Drug Delivery Systems" | iBB | Scoop.it

We are excited to announce the call for submissions for the upcoming Special Issue of Pharmaceutics, titled "Novel Micro/Nanomaterial Based Drug Delivery Systems for Theranostic Applications". As guest editors, Pedro Fonte, Pedro Brandão, and Sofia Duarte, we eagerly invite your contributions to this innovative and rapidly evolving field. This Special Issue aims to highlight the latest advancements in micro- and nanomaterials, particularly in their application to drug delivery systems for theranostic purposes. The intersection of nanotechnology and medicine is paving the way for breakthroughs in healthcare, allowing for the creation of more effective drug delivery mechanisms that can diagnose and treat diseases simultaneously. Our focus is on how these advanced materials can improve therapeutic efficacy, reduce side effects, and transform disease management. For more information, please visit the Special Issue page.

iBB's insight:

The submission deadline is 30 November 2024. All submissions will undergo the peer-review process of Pharmaceutics, and authors will enjoy benefits such as open access and high visibility, rapid turn-around time averaging 16.6 days from submission to first decision, and a free English editing service after acceptance.

We kindly request a short tentative abstract (100–150 words) describing your contribution's topic within the next month if you are interested in participating. For any questions or to submit your abstract, please contact us.

No comment yet.
Scoop.it!

The Effect of Recombinant Protein Production in Lactococcus lactis Transcriptome and Proteome

The Effect of Recombinant Protein Production in Lactococcus lactis Transcriptome and Proteome | iBB | Scoop.it

Lactococcus lactis is a food-grade, and generally recognized as safe, bacterium, which making it ideal for producing plasmid DNA (pDNA) or recombinant proteins for industrial or pharmaceutical applications. A paper published in Microorganisms by Sofia Duarte and Gabriel Monteiro from BERG-iBB reviews the major findings from L. lactis transcriptome and proteome studies, with an overexpression of native or recombinant proteins. These studies provide important insights on how to engineer the plasmid vectors and/or the strains in order to achieve high pDNA or recombinant proteins yields, with high quality standards. 

Scoop.it!

Cover of Biotechnology Journal Highlights iBB's Work on Lactic Acid Bacteria

Cover of Biotechnology Journal Highlights iBB's Work on Lactic Acid Bacteria | iBB | Scoop.it

BERG-iBB researchers led by Gabriel Monteiro are engineering lactic acid bacteria and plasmid vectors in order to develop a flexible platform for biomolecule production. The cover image of the August issue of Biotechnology Journal highlights a recent contribution of the group. The work is part of the FCT-funded project LactoSynt.

No comment yet.
Scoop.it!

Sofia Duarte Joins LactoSynt Team as Research Scientist

Sofia Duarte Joins LactoSynt Team as Research Scientist | iBB | Scoop.it

Sofia Duarte has joined the team of the FCT-funded project "LactoSynt: Lactic Acid Bacteria as Cell Factories: a Synthetic Biology Approach for Plasmid DNA and Recombinant Protein Production". During the next three years Sofia will be responsible for engineering lactic acid bacteria and plasmid vectors with the goal of developing a flexible platform for biomolecule production. The project is a joint collaboration between iBB groups BERG (Gabriel Monteiro) and BSRG (Leonilde Moreira).

No comment yet.
Scoop.it!

Sofia Duarte Defends PhD Thesis in Biotechnology and Biosciences

Sofia Duarte Defends PhD Thesis in Biotechnology and Biosciences | iBB | Scoop.it

Sofia de Oliveira Duarte has defended her Ph D thesis in Biotechnology and Biosciences at Instituto Superior Técnico on the 16th April 2018. During the last years, and under the supervision of Gabriel Monteiro from BERG-IBB and Lígia Rodrigues from University of Minho, Sofia has investigated the possibility of engineering lactic acid bacteria to produce plasmids and proteins. The title of her thesis is "Lactic acid bacteria as cell factories: A synthetic biology approach for plasmid DNA and recombinant protein production”.

No comment yet.
Scoop.it!

Invitation to Contribute to the Special Issue "Liposomes Applied in Drug Delivery Systems" published in Pharmaceutics

Invitation to Contribute to the Special Issue "Liposomes Applied in Drug Delivery Systems" published in Pharmaceutics | iBB | Scoop.it

We are pleased to invite you to contribute to the Special Issue titled "Liposomes Applied in Drug Delivery Systems" published in Pharmaceutics. This issue, edited by Dr. Pedro Fonte, Dr. Teresa Esteves and Dr. Sofia de Oliveira Dias Duarte, focuses on the recent advancements and applications of liposomes in drug delivery, emphasizing their pivotal role in targeted therapy and diagnostics. Since the emergence of liposomes in pharmaceutical research, there has been a significant drive to bridge the gap between laboratory innovation and market application. We aim to cover a broad spectrum of topics, including but not limited to the design and synthesis of liposomes, advancements in targeted drug delivery using liposomes, the role of liposomes in gene therapy, innovations in liposomal formulations for enhanced drug stability, and their application in specific health problems like cancer therapy and regenerative medicine. For more information, please visit the Special Issue page.

We eagerly anticipate your valuable contributions to this exciting Special Issue.

iBB's insight:

 

The submission deadline is 30 September 2024. All submissions will undergo the peer-review process of Pharmaceutics, and authors will enjoy benefits such as open access and high visibility, rapid turn-around time averaging 16.6 days from submission to first decision, and a free English editing service after acceptance.

We kindly request a short tentative abstract (100–150 words) describing your contribution's topic within the next month if you are interested in participating. For any questions or to submit your abstract, please contact us.

 https://www.mdpi.com/journal/pharmaceutics/special_issues/QPW7W5613K

 

 

No comment yet.
Scoop.it!

Plasmid Replicons for the Production of Biopharmaceuticals by Lactococcus lactis Cell Factories

Plasmid Replicons for the Production of Biopharmaceuticals by Lactococcus lactis Cell Factories | iBB | Scoop.it

While Lactococcus lactis is traditionally associated with the fermented food industry, applications of these bacteria have been spreading to the pharmaceutical industry. The goal is to use L. lactis as cell factories for the production of added-value recombinant proteins and plasmid DNA (pDNA) for DNA vaccination, as a safer and industrially profitable alternative to the traditional Escherichia coli host. In a recent review in International Molecular Sciences, Sofia Duarte and Gabriel Monteiro from BERG-iBB critically systematize the plasmid replicons available for the production of pharmaceutical-grade pDNA and recombinant proteins by L. lactis. The work is funded by the LactoSynt project.

No comment yet.
Scoop.it!

Increasing Plasmid Copy Number in Lactococcus lactis

Increasing Plasmid Copy Number in Lactococcus lactis | iBB | Scoop.it

The lipopolysaccharide-free Lactococcus lactis is an interesting alternative to E. coli for plasmid production. A key requirement for L. lactis‐based plasmid manufacturing is the availability of high‐copy number plasmids. In a recent publication in Biotechnology Journal, BERG-iBB researchers led by Gabriel Monteiro describe how engineering of the repDE Ribosome Binding Site led to an increase in the copy number  of plasmid pTRKH3 in L. lactis LMG19460 cells.  The number of copies of mutant pTRKH3‐b increased up to 215 copies per chromosome, which corresponds to a 3.5 fold increase when compared to the non‐modified pTRKH3. The new mutant is an important step towards the establishment of lactic acid bacteria as viable plasmid producers. The work was developed in the context of the FCT-funded, LactoSynt project.

No comment yet.
Scoop.it!

Effects of Clay's Chemical Interactions on Biocementation

Effects of Clay's Chemical Interactions on Biocementation | iBB | Scoop.it

Biocementation, or microbially induced calcite precipitation (MICP), is a technique currently being appraised for the improvement of sandy soils. A recent study led by Gabriel Monteiro from BERG-iBB and Rafaela Cardoso from IST describes an investigation of the effect of clay chemical interactions on biocementation with Sporosarcina pasteurii. Results show that osmotic effects play a key role in biocimentation and that MICP treatment in clayey soils is more complex than in sands with reduced clay content. Click on title to learn more about the research published in Applied Clay Science.

No comment yet.